DTIL – Precision BioSciences Inc.
DTIL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
6.15
Margin Of Safety %
Put/Call OI Ratio
0.05
EPS Next Q Diff
-0.27
EPS Last/This Y
1.39
EPS This/Next Y
0.26
Price
7.23
Target Price
32
Analyst Recom
1
Performance Q
83.04
Upside
-1,232.0%
Beta
1.32
Ticker: DTIL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | DTIL | 7.31 | 0.07 | 7.67 | 1053 |
| 2026-04-24 | DTIL | 7.05 | 0.10 | 10.00 | 1076 |
| 2026-04-27 | DTIL | 7.04 | 0.10 | 10.00 | 1076 |
| 2026-04-28 | DTIL | 7.11 | 0.12 | 0.00 | 1103 |
| 2026-04-29 | DTIL | 6.87 | 0.12 | 0.00 | 1103 |
| 2026-04-30 | DTIL | 7.16 | 0.12 | 1.00 | 1104 |
| 2026-05-01 | DTIL | 7.28 | 0.12 | 0.00 | 1106 |
| 2026-05-04 | DTIL | 7.66 | 0.12 | 0.00 | 1109 |
| 2026-05-05 | DTIL | 7.45 | 0.12 | 0.00 | 1113 |
| 2026-05-06 | DTIL | 7.57 | 0.12 | 0.00 | 1113 |
| 2026-05-07 | DTIL | 7.47 | 0.12 | 0.02 | 1115 |
| 2026-05-08 | DTIL | 7.65 | 0.12 | 1.75 | 1158 |
| 2026-05-11 | DTIL | 7.86 | 0.13 | 0.06 | 1178 |
| 2026-05-12 | DTIL | 8.22 | 0.13 | 0.08 | 1211 |
| 2026-05-13 | DTIL | 8.34 | 0.13 | 0.25 | 1234 |
| 2026-05-14 | DTIL | 8.08 | 0.13 | 0.27 | 1239 |
| 2026-05-15 | DTIL | 7.26 | 0.13 | 0.15 | 1232 |
| 2026-05-18 | DTIL | 6.96 | 0.07 | 0.00 | 392 |
| 2026-05-19 | DTIL | 6.89 | 0.06 | 0.00 | 410 |
| 2026-05-20 | DTIL | 7.16 | 0.06 | 0.01 | 412 |
| 2026-05-21 | DTIL | 7.14 | 0.05 | 999.99 | 571 |
| 2026-05-22 | DTIL | 7.21 | 0.05 | 0.00 | 571 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | DTIL | 7.33 | 63.8 | - | -3.53 |
| 2026-04-24 | DTIL | 7.06 | 63.4 | - | -3.16 |
| 2026-04-27 | DTIL | 7.06 | 63.4 | - | -3.16 |
| 2026-04-28 | DTIL | 7.11 | 63.4 | - | -3.16 |
| 2026-04-29 | DTIL | 6.89 | 63.4 | - | -3.16 |
| 2026-04-30 | DTIL | 7.16 | 63.4 | - | -3.16 |
| 2026-05-01 | DTIL | 7.28 | 63.4 | - | -3.16 |
| 2026-05-04 | DTIL | 7.64 | 63.4 | - | -3.16 |
| 2026-05-05 | DTIL | 7.46 | 63.4 | - | -3.16 |
| 2026-05-06 | DTIL | 7.57 | 63.4 | - | -3.16 |
| 2026-05-07 | DTIL | 7.50 | 63.4 | - | -3.16 |
| 2026-05-08 | DTIL | 7.67 | 63.4 | - | -3.18 |
| 2026-05-11 | DTIL | 7.84 | 54.0 | - | -3.18 |
| 2026-05-12 | DTIL | 8.18 | 54.0 | - | -3.18 |
| 2026-05-13 | DTIL | 8.36 | 54.0 | - | -3.18 |
| 2026-05-14 | DTIL | 8.08 | 54.0 | - | -3.18 |
| 2026-05-15 | DTIL | 7.29 | 54.0 | - | -2.17 |
| 2026-05-18 | DTIL | 6.93 | 71.8 | - | -2.17 |
| 2026-05-19 | DTIL | 6.90 | 71.8 | - | -2.17 |
| 2026-05-20 | DTIL | 7.16 | 71.8 | - | -2.17 |
| 2026-05-21 | DTIL | 7.16 | 71.8 | - | -2.17 |
| 2026-05-22 | DTIL | 7.23 | 71.8 | - | -2.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | DTIL | -1.84 | 38.26 | 5.09 |
| 2026-04-24 | DTIL | -3.67 | 38.26 | 5.09 |
| 2026-04-27 | DTIL | -3.67 | 38.26 | 5.42 |
| 2026-04-28 | DTIL | -3.67 | 38.26 | 5.42 |
| 2026-04-29 | DTIL | -3.67 | 38.26 | 5.42 |
| 2026-04-30 | DTIL | -3.66 | 38.26 | 5.42 |
| 2026-05-01 | DTIL | -3.66 | 38.26 | 5.42 |
| 2026-05-04 | DTIL | -3.66 | 23.44 | 5.42 |
| 2026-05-05 | DTIL | -3.49 | 23.44 | 5.42 |
| 2026-05-06 | DTIL | -3.49 | 23.44 | 5.42 |
| 2026-05-07 | DTIL | -3.49 | 23.44 | 5.42 |
| 2026-05-08 | DTIL | -3.49 | 23.44 | 5.42 |
| 2026-05-11 | DTIL | -3.49 | 23.68 | 5.42 |
| 2026-05-12 | DTIL | -3.49 | 23.68 | 6.15 |
| 2026-05-13 | DTIL | -3.49 | 23.68 | 6.15 |
| 2026-05-14 | DTIL | -3.49 | 23.68 | 6.15 |
| 2026-05-15 | DTIL | -3.49 | 23.68 | 6.15 |
| 2026-05-18 | DTIL | -3.49 | 23.32 | 6.15 |
| 2026-05-19 | DTIL | -3.49 | 23.32 | 6.15 |
| 2026-05-20 | DTIL | -3.49 | 23.32 | 6.15 |
| 2026-05-21 | DTIL | -3.49 | 23.32 | 6.15 |
| 2026-05-22 | DTIL | -3.49 | 23.32 | 6.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.34
Avg. EPS Est. Current Quarter
-0.6
Avg. EPS Est. Next Quarter
-0.61
Insider Transactions
-3.49
Institutional Transactions
23.32
Beta
1.32
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
2
Fair Value
Quality Score
29
Growth Score
29
Sentiment Score
7
Actual DrawDown %
98.3
Max Drawdown 5-Year %
-99.2
Target Price
32
P/E
Forward P/E
PEG
P/S
4.14
P/B
2.45
P/Free Cash Flow
EPS
-3.72
Average EPS Est. Cur. Y
-2.17
EPS Next Y. (Est.)
-1.91
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-98.7
Relative Volume
0.66
Return on Equity vs Sector %
-83
Return on Equity vs Industry %
-67.3
EPS 1 7Days Diff
1
EPS 1 30Days Diff
1.36
EBIT Estimation
◆
DTIL
Healthcare
$7.23
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
49.7
Range 1M
35.2%
Sup Dist
4.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
26.3%
EPS NY
7.6%
52W%
70%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+342.6% upside
Upside
+342.6%
Quality
29
Precision BioSciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 66
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL
Latest News
—
Caricamento notizie per DTIL…
stock quote shares DTIL – Precision BioSciences Inc. Stock Price stock today
news today DTIL – Precision BioSciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading